Core Viewpoint - GSK's stock fell over 5% to $43.10 following the FDA's approval of its blood cancer drug Blenrep, which has limited indications and a narrow commercial opportunity despite the positive regulatory outcome [1] Group 1: FDA Approval - GSK received FDA approval for Blenrep as a third-line therapy for adult patients who have undergone at least two prior treatments, contrary to GSK's expectation for it to be approved as a second-line therapy [1] - The approval is seen as a positive development, but the limited indication may dampen its commercial prospects [1] Group 2: Market Impact - UBS analysts noted that the requirement for patients to undergo ophthalmic examinations before each dose could further disappoint GSK [1] - The combination of a smaller indication range and strict risk evaluation and mitigation strategies may reduce the drug's market potential [1]